other material
confidence high
sentiment positive
materiality 0.75
Inhibrx reports 20% ORR with ozekibart combo in late-line CRC; BLA submitted for chondrosarcoma
Inhibrx Biosciences, Inc.
- ORR of 20% in 45 evaluable patients vs historical 1-6% for standard of care; responses durable >6 months.
- Median PFS 5.5 months; 42% progression-free at 6 months; DCR 87%.
- Manageable safety, mostly Grade 1-2 diarrhea, fatigue, nausea; no significant liver toxicity despite 68% with liver metastases.
- Plans to meet FDA in H2 2026 for first-line registrational trial; accelerate pathways for 4th-line CRC and refractory Ewing sarcoma.
- BLA submitted to FDA for ozekibart in conventional chondrosarcoma in April 2026.